ClinicalTrials.gg
CompletedNCT02744196ALTERRAUpdated Jan 25, 2018

Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis

A Phase 3 interventional study of Acellbia and Placebo in Rheumatoid Arthritis, sponsored by Biocad. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-01-25.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jan 2015, registered Apr 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
32nd of 63
159 · median 159
Started
2015
with 2 others
Phase 3
27 of 63
1 open now
Registered
55th of 63
by date
Lead sponsor
2 of 63
Biocad

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 32nd largest by enrollment, is one of 3 that started in 2015, is one of 27 in phase 3, and was the 55th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The mail goal of this study is to establish superiority in efficacy of Acellbia® applied in a dose of 600 mg (Day 1 and Day 15) in combination with methotrexate in patients with active RA seropositive previously untreated with biological therapy, compared to standard therapy with methotrexate.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • rheumatoid arthritis
  • rheumatism
  • Acellbia
  • methotrexate
  • biologic therapy
  • monoclonal antibody
  • rituximab
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Written . Age from 18 to 80 years. Rheumatoid arthritis diagnosed at least 6 months before informed consent signing Presence of more than 8 swollen and more than 8 painful joints at screening. C-reactive protein 7 mg/l or more AND/OR erythrocyte sedimentation rate 28 mm/hour or more.

Antibodies to citrullinated cyclic peptide 20 U/ml or more AND/OR rheumatoid factor-IgM higher than upper normal limit.

Documented regular methotrexate intake for 12 weeks, stable dose from 10 to 25 mg/week during last 4 weeks before signing informed consent.

Exclusion criteria

Exclusion Criteria:

Methotrexate intolerance. Felty's syndrome. Patient functional status - IV class according to ACR. Previous use of biologic drugs to treat rheumatoid arthritis, biologic drugs that deplete CD20-lymphocytes, azathioprine use in the last 28 days prior to signing, leflunomide use in the last 8 weeks prior to informed consent signing, sulphasalazine/hydroxyquinoline use in the last 28 days prior to informed consent signing, intraarticular use of in the last 4 weeks prior to informed consent signing, patient requires prednisolone (or analogues) in a dose more than 10 mg/day or dose is unstable during 4 weeks prior to informed consent signing, requirement in non-steroid antiinflammatory drugs if their dose was not stable during last 8 weeks prior to informed consent signing.

Patient has inflammatory joint disease otherwise than rheumatoid arthritis or systemic diseases.

Full list of inclusion and exclusion criteria can be found in Study Protocol.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Acellbia + methotrexate

    106 patients of this group will receive methotrexate in combination with a drug Acellbia to be used at a dose of 600 mg as a slow intravenous infusion carried out on day 1 and day 15. If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)\> 2,6 points), the therapy with Acellbia is repeated by the same scheme - 2 infusion at a dose of 600 mg at intervals of 14 days.

    Biological: Acellbia · Drug: Methotrexate

  • Placebo comparator
    Placebo + methotrexate

    53 patients of this group will receive methotrexate in combination with a placebo to be used as a slow intravenous infusion carried out on day 1 and day 15. If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)\> 2,6 points), the patient receives open therapy with Acellbia is initiated: 2 infusion at a dose of 600 mg at intervals of 14 days.

    Biological: Acellbia · Drug: Placebo · Drug: Methotrexate

Interventions

  • BiologicalAcellbia

    Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.

    Also known as: rituximab

  • DrugPlacebo

    Placebo solution will look identical to the Acellbia solution.

06

What researchers measure

Primary outcomes

  1. Percentage of patients who developed ACR20 response on 24 week of therapy

    The proportion of patients achieving at least a 20% improvement in ACR criteria at 24 weeks of therapy.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of patients who developed ACR50 and ACR70 response on 24 week of therapy

    The proportion of patients achieving at least 50% and 70% improvement in ACR criteria at 24 weeks of therapy.

    Time frame: Week 24

  2. Percentage of patients who developed ACR20, ACR50 and ACR70 response on 16 week of therapy

    The proportion of patients achieving at least 20%, 50% and 70% improvement in ACR criteria after 16 weeks of therapy.

    Time frame: Week 16

  3. Change in average DAS28-4 (ESR) score after 24 weeks of therapy

    Change in average DAS28-4 (ESR) score after 24 weeks of therapy

    Time frame: Week 24

  4. Change in average HAQ-DI score after 24 weeks of therapy

    Time frame: Week 24

  5. Change in average score according to modified Sharp method of assessment after 24 weeks of therapy

    Time frame: Week 24

  6. Change in average score of erosions according to modified Sharp method of assessment after 24 weeks of therapy

    Time frame: Week 24

  7. Change in average score of joint spase narrowing according to modified Sharp method of assessment after 24 weeks of therapy

    Time frame: Week 24

  8. Percentage of patients with progression of disease according to modified Steinbrocker method of assessment after 24 weeks of treatment

    Time frame: Week 24

  9. Percentage of patients who developed ACR20, ACR50 and ACR70 response on 52 week of therapy

    The proportion of patients achieving at least 20%, 50% and 70% improvement in ACR criteria after 52 weeks of therapy.

    Time frame: Week 52

  10. Change in average DAS28-4 (ESR) score after 52 weeks of therapy

    Change in average DAS28-4 (ESR) score after 52 weeks of therapy

    Time frame: Week 52

  11. Change in average HAQ-DI score after 52 weeks of therapy

    Time frame: Week 52

  12. Change in average score according to modified Sharp method of assessment after 52 weeks of therapy

    Time frame: Week 52

  13. Change in average score of erosions according to modified Sharp method of assessment after 52 weeks of therapy

    Time frame: Week 52

  14. Change in average score of joint space narrowing according to modified Sharp method of assessment after 52 weeks of therapy

    Time frame: Week 52

  15. Percentage of patients with progression of disease according to modified Steinbrocker method of assessment after 52 weeks of treatment

    Time frame: Week 52

  16. Frequency and severity of AE/SAE

    Frequency and severity of AE/SAE in patients who received at least one injection of study drug/placebo

    Time frame: 52 weeks

  17. Frequency of AE 3-4 grade CTCAE 4.03

    Frequency of AE 3-4 grade CTCAE 4.03 in patients who received at least one injection of study drug/placebo

    Time frame: 52 weeks

  18. Frequency of premature withdrawal due to AE/SAE

    Time frame: 52 weeks

  19. Percentage of patients who have developed binding and neutralizing antibodies to rituximab on week 24 and week 52

    Time frame: Week 24, Week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Feb 2017, 25 months.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 25 months is close to that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2016
First posted
Apr 20, 2016
StartActual
Jan 2015
Primary completionActual
Feb 2017
CompletionActual
Aug 2017
Last update
Jan 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02744196
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Apr 20, 2016
Start date
Jan 2015
Primary completion
Feb 2017
Completion
Aug 2017
Last update
Jan 25, 2018

Study contacts

Roman Ivanov, PhD
study chair · JCS BIOCAD

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Methotrexate

Start the discussion